Literature DB >> 9744810

Dimeric and tetrameric forms of catalytically active transmembrane CD38 in transfected HeLa cells.

S Bruzzone1, L Guida, L Franco, E Zocchi, G Corte, A De Flora.   

Abstract

CD38, a type II transmembrane glycoprotein, behaves as a catalytically active transporter responsible for ectocellular generation of cyclic ADP-ribose (cADPR) from NAD+ and for subsequent influx of cADPR across membranes [Franco, L., Guida, L., Bruzzone, S., Zocchi, E., Usai, C. and De Flora, A. (1998) FASEB J. in press]. cADPR regulates intracellular calcium homeostasis by releasing calcium from responsive stores. The cADPR-transporting function of CD38 requires channel-generating oligomeric forms of the protein rather than the 46 kDa monomers that have been described so far in CD38+ cells. Here we demonstrate that CD38, both in reconstituted proteoliposomes and in CD38-transfected HeLa cells, is a mixture of catalytically active monomers, homodimers and homotetramers. A soluble recombinant form of CD38 corresponding to its ectocellular region proved to be monomeric. Thus, association of native CD38 with either artificial or natural membranes seems to result in a reversible juxtaposition of monomers suitable to cADPR-transporting activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744810     DOI: 10.1016/s0014-5793(98)00929-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Identification of human plasma cells with a lamprey monoclonal antibody.

Authors:  Cuiling Yu; Yanling Liu; Justin Tze Ho Chan; Jiefei Tong; Zhihua Li; Mengyao Shi; Dariush Davani; Marion Parsons; Srijit Khan; Wei Zhan; Shuya Kyu; Eyal Grunebaum; Paolo Campisi; Evan J Propst; David L Jaye; Suzanne Trudel; Michael F Moran; Mario Ostrowski; Brantley R Herrin; F Eun-Hyung Lee; Ignacio Sanz; Max D Cooper; Götz Ra Ehrhardt
Journal:  JCI Insight       Date:  2016-03-17

2.  Abscisic acid activates the murine microglial cell line N9 through the second messenger cyclic ADP-ribose.

Authors:  Nicoletta Bodrato; Luisa Franco; Chiara Fresia; Lucrezia Guida; Cesare Usai; Annalisa Salis; Iliana Moreschi; Chiara Ferraris; Claudia Verderio; Giovanna Basile; Santina Bruzzone; Sonia Scarfì; Antonio De Flora; Elena Zocchi
Journal:  J Biol Chem       Date:  2009-03-27       Impact factor: 5.157

Review 3.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Authors:  Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

Review 4.  Enzymology of extracellular NAD metabolism.

Authors:  Massimiliano Gasparrini; Leonardo Sorci; Nadia Raffaelli
Journal:  Cell Mol Life Sci       Date:  2021-03-23       Impact factor: 9.261

5.  Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque.

Authors:  Enza Ferrero; Monia Orciani; Paola Vacca; Erika Ortolan; Sergio Crovella; Fausto Titti; Franca Saccucci; Fabio Malavasi
Journal:  BMC Immunol       Date:  2004-09-21       Impact factor: 3.615

6.  Ca(2+) signaling occurs via second messenger release from intraorganelle synthesis sites.

Authors:  Lianne C Davis; Anthony J Morgan; Margarida Ruas; Julian L Wong; Richard M Graeff; Albert J Poustka; Hon Cheung Lee; Gary M Wessel; John Parrington; Antony Galione
Journal:  Curr Biol       Date:  2008-10-28       Impact factor: 10.834

7.  Detection of Human CD38 Using Variable Lymphocyte Receptor (VLR) Tetramers.

Authors:  Srijit Khan; Yanling Liu; Laura M Ernst; Leslie Y T Leung; Patrick Budylowski; Shilan Dong; Paolo Campisi; Evan J Propst; Nikolaus E Wolter; Eyal Grunebaum; Mario Ostrowski; Götz R A Ehrhardt
Journal:  Cells       Date:  2020-04-12       Impact factor: 6.600

Review 8.  Roles of CD38 in the Immune Response to Infection.

Authors:  Estibaliz Glaría; Annabel F Valledor
Journal:  Cells       Date:  2020-01-16       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.